Senolytic breakthrough brings Longevity one giant leap closer

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

Mayo clinic researchers demonstrate senolytic drugs clearing senescent cells in humans for the first time.

In a landmark trial, researchers from the Mayo clinic have demonstrated for the first time in humans that senolytic drugs can remove senescent cells from the body. The data follows a large number of significant results shown in animals, and promising human data released by a competing trial, to boost investor confidence in the viability of senolytics as future Longevity drugs.

The small trial, designed to test safety and feasibility, was conducted on patients with diabetes-related kidney disease. Upon dual administration of the senolytic drugs dasatinib and quercetin, markers of senescent cells in the patient’s skin and adipose tissue were measured to have decreased. The researchers report their findings in EBioMedicine [1].

Longevity.Technology: This is incredible news. Despite a slew of animal results and promising data from Unity Biotech’s Phase 2 trial into its senolytics, no public data until now has shown that senolytics have the same senescent cell clearing effect upon human bodies as they do animal ones — a fact that has long dampened enthusiasm among investors canny enough to know the treacherous tightrope drugs must tread between successful animal and human results.

The TRL score for this Longevity.Technology domain is currently set at: ‘Late proof of concept demonstrated in real life conditions.’

The TRL score for the technology addressed in this article is: “Technology refined and ready for initial human trials.”

For those who are wondering what senescent cells are, and why a result that shows their clearance in humans could prove exciting for Longevity: senescent cells are old cells that (having passed the limit of cell division called the Hayflick limit) can no longer divide. Accumulating over time in the body, these ‘zombie’ cells secrete inflammatory molecules called cytokines that cause damage to neighbouring tissues; triggering illness, inflammation and contributing to the symptoms of frailty associated with aging. They may also, according to a new body of research, be a potential cause of many age-related diseases like Alzheimer’s, Parkinson’s, idiopathic pulmonary fibrosis (IPF) and chronic kidney disease.

If this is true, then senolytics could provide a powerful solution to age-related conditions, halting their progress upstream before symptoms even manifest.

“Senescent cells can develop in all mammals in response to disease, injury, or cancerous mutations. Senolytic drugs do not interfere with generation of senescent cells, which could lead to cancer. However, once formed, senescent cells can contribute to developing cancers, multiple other diseases, and consequences of aging,” says James Kirkland, senior author and head of the Robert and Arlene Kogod Center on Aging.

“By targeting senescent cells with senolytics in mice, we can delay, prevent, or treat multiple diseases and increase health and independence during remaining years of life,” says Dr. Kirkland. “As we increase our understanding of these drugs and their effects, we hope there may be benefits for a range of human diseases and disorders.”

The Mayo clinic’s previously released results showed that patients suffering from IPF experienced signs of increased physical function when administered with a short-term dosage of dasatinib and quercetin. Now, this trial may have revealed the mechanism of action as being the same as it has been seen to be in mice: the clearance of senescent cells.

“This small-scale clinical trial is a significant step forward for translation of senolytic therapies,” says Ronald Kohanski, Ph.D., deputy director, Division of Aging Biology, National Institute on Aging. “The demonstration that senescent cell numbers can be reduced in two tissues in humans is an important advance based on the compelling evidence from studies in laboratory mice.”

But don’t go popping any pills yet. Senolytics are still very new, and scientists aren’t sure of their long term effects on the body. As the Mayo researchers conclude in their paper:

“The field of senolytics is new … In addition to side effects related to individual senolytic drugs known from other contexts in which those drugs have been used, there could turn out to be serious side-effects of senolytics as a class, which are not yet known. We caution against the use of senolytic agents outside the context of clinical trials until more is known about their effects and side effects.”

[1] https://www.ebiomedicine.com/article/S2352-3964(19)30591-2/fulltext

Ben Turner
Staff Writer Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Printers that can now print DNA

DNA Script obtains CE Mark for SYNTAX DNA printing platform. DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Young blood: discover the possibilities of plasma based therapy

The evolution of plasma-based therapeutics is accelerating – our FREE report cuts through the young blood hype for the lowdown on the latest therapies. Our...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

    Subscribe to our newsletter